News

The antibiotic Bedaquiline (BDQ) was approved in 2014 specifically for the treatment of multidrug-resistant (MDR) tuberculosis (TB) and has since been an important component of successful MDR TB

Patients can participate in medical research as active partners. Researchers should consider their needs and their unique expertise in the research process, as it is a valuable resource. The Health

Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF

We still do not understand exactly how antibiotics kill bacteria. However, this understanding is necessary if we want to develop new antibiotics. And that is precisely what is urgently needed, because

According to the World Health Organisation (WHO), approximately 1.5 million people die each year from tuberculosis (TB), a disease of the lungs caused by Mycobacterium tuberculosis. People with a

The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available

This is what ideal medicine would look like: Doctors could specifically alter molecular processes in diseased cells in the body and thus causally cure patients. This is the goal of the German Centers

The human immunodeficiency virus HIV-1 is able to infect various tissues in humans. Once inside the cells, the virus integrates its genome into the cellular genome and establishes persistent

A long-term study by the Research Center Borstel, Leibniz Lung Center was able to show that the therapeutic success of patients with multidrug-resistant tuberculosis is much higher than previously

How can the results of molecular resistance tests be used to optimize drug therapy for tuberculosis? An international panel of experts has updated a consensus document outlining how to interpret